GW Pharmaceuticals to let Almirall sell cannabis-derived drug in Mexico
This article was originally published in Scrip
Executive Summary
GW Pharmaceuticals has amended its Sativex licence agreement with Almirall. The Spanish firm now has rights to market Sativex in Mexico and GW is entitled to a new near term milestone payment of €12 million (£10 million).